Fusion Antibodies (LSE:FAB) Total Assets : £2.06 Mil (As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Total Assets?

Fusion Antibodies's Total Assets for the quarter that ended in Sep. 2023 was £2.06 Mil.

During the past 12 months, Fusion Antibodies's average Total Assets Growth Rate was -43.60% per year. During the past 3 years, the average Total Assets Growth Rate was -25.40% per year. During the past 5 years, the average Total Assets Growth Rate was -9.30% per year.

During the past 9 years, Fusion Antibodies's highest 3-Year average Total Assets Growth Rate was 116.70%. The lowest was -25.40%. And the median was 19.50%.

Total Assets is connected with ROA %. Fusion Antibodies's annualized ROA % for the quarter that ended in Sep. 2023 was -131.75%. Total Assets is also linked to Revenue through Asset Turnover. Fusion Antibodies's Asset Turnover for the quarter that ended in Sep. 2023 was 0.26.

Fusion Antibodies Total Assets Historical Data

The historical data trend for Fusion Antibodies's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Total Assets Chart

Fusion Antibodies Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Assets

Get a 7-Day Free Trial

6.24

6.04

5.83

4.92

2.06

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Total Assets	Get a 7-Day Free Trial											5.37	4.92	3.98	2.06	2.06

Fusion Antibodies Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Fusion Antibodies's Total Assets for the fiscal year that ended in Mar. 2023 is calculated as

Total Assets	=	Total Equity (A: Mar. 2023 )	+	Total Liabilities (A: Mar. 2023 )
	=	1.123	+	0.939
	=	2.06

Fusion Antibodies's Total Assets for the quarter that ended in Sep. 2023 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2023 )	+	Total Liabilities (Q: Sep. 2023 )
	=	1.454	+	0.604
	=	2.06

Fusion Antibodies (LSE:FAB) Total Assets Explanation

Total Assets is connected with ROA %.

Fusion Antibodies's annualized ROA % for the quarter that ended in Sep. 2023 is

ROA %	=	Net Income (Q: Sep. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	-2.714	/	( (2.062	+	2.058)	/ 2 )
	=	-2.714	/	2.06
	=	-131.75 %

Note: The Net Income data used here is two times the semi-annual (Sep. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Fusion Antibodies's Asset Turnover for the quarter that ended in Sep. 2023 is

	Asset Turnover
=	Revenue (Q: Sep. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
=	0.541	/	( (2.062	+	2.058)	/ 2 )
=	0.541	/	2.06
=	0.26

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Fusion Antibodies Total Assets Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Antibodies (LSE:FAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL

Website

https://www.fusionantibodies.com

Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022